Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints

Korábbi kezelés

• Participants who have been taking medication of typical antipsychotics, mood stabilizer, cognitive enhancer including donepezil, rivastigamine, galantamine, and memantine within 1months.
• Participants who had previous history of liver disease or renal disease

Más betegség

• Diagnosed as schizophrenia, bipolar disorder, PTSD, OCD or other significant mental disorder under the criteria of DSM-5 (only the participants who had depressive disorder, sleep disorder, and the anxiety disorder are allowed to be included)
• Who have medically unstable disease (only the participants, who have diabetes mellitus or hypertension under control with stable medication for 3 months could be included)
• Diagnosed as dementia or mild cognitive impairment
• Participants who had allergic reaction to choline alfoscerate
• Other specific condition, which could be inappropriate for the trial inclusion, under the judgement of the principal investigator

Egyéb

• Participants who are already taking choline alfoscerate within 4 weeks of period

• Age ≥ 60 years
• Diagnosed as MDD under the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and confirmed with MINI-Depression
• HAM-D ≥ 14
• MMSE ≥ 20
• Who had continuous subjective memory complaints more than 6 months before the period of screening
• Who had taking antidepressants longer than 1 month in the period of screening